Extending the current grace period for reinjection of the contraceptive shot depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer) from two to four weeks does not increase pregnancy risk and could increase contraceptive continuation, indicate findings from a newly published study.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content